Integra LifeSciences Holdings Corporation has announced the launch of the Integra® CUSA® NXT Inferior Forward Bone Tip for its CUSA® NXT Ultrasonic Tissue Ablation System.
Neuro
St.Jude Third Quarter Results Suggest It’s Still Taking The Pain
It’s not all doom and gloom for St.Jude, but its hard to find much good news from the revenue lines. AF is the shining star from the sales perspective, and the bottom line has been tarnished by inclusion of costs associated with reorganisation
Stryker Makes Intentions Clear In Neuro Space With Acquisition Of Flow Diverter Company Surpass Medical
Stryker’s Neuro Division bag is filling nicely with the newly announced acquisition of Surpass Medical, a company with interesting Neuro flow diverter technology in its portfolio.
Peripheral Nerve Stimulation Reduces Headache Days Says Migraine Study
Data published today in the Headache Society journal Cephalagia shows significant reductions in pain, headache days and migraine-related disability when Peripheral Nerve Stimulation therapy is applied.
Deep Brain Stimulation Advances With EU Launch of Boston Sci’s Vercise™ DBS System
Boston Scientific Corporation has received CE Mark approval for use of its Vercise™ Deep Brain Stimulation System for the treatment of Parkinson’s disease. The company says this is the first and only commercially available DBS system to incorporate multiple independent current control, which is designed to selectively stimulate targeted areas in the brain.
NeuroSigma’s Monarch eTNS System to be Unveiled in London
NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that its Monarch™ eTNS™ system for the adjunctive treatment of epilepsy and depression will make its debut at the 10th European Congress on Epileptology, which takes place in London, England from September 30 to October 4, 2012.
HyperBranch Completes Clinical Enrollment In FDA Dural Sealant Study
Hyperbranch possesses its own particular hydrogel which is already sold in Europe as a dural sealant for use following neurosurgery. Now the company has taken a step towards FDA approval with the news that it has completed enrollment in its pivotal IDE study.
CE Mark For St.Jude’s Eon™ Mini Migraine Neurostimulator
St. Jude Medical, Inc. has announced it has received European CE Mark approval of its Eon™ family of neurostimulators for patients with intractable chronic migraine. The range includes the Eon Mini, which St.Jude says is the world’s smallest rechargeable neurostimulator with the longest-lasting battery in its class.
MRI Interventions And Brainlab Launch European Commercialisation Effort With First ClearPoint Case In Europe
ClearPoint Case Performed in Grenoble, France, the Birthplace of Deep Brain Stimulation Therapy
The Power Of The Registry: 90% Of Codman Enterprise® VRD Patients Independent, Free Of Significant Disabilities At 21 Months
Registry data published in Neurosurgery suggests Codman’s Enterprise stent-assisted coil embolization system is an effective tool in the occlusion of neurovascular aneurysms with positive outcomes at 21 months.
CE Mark For Neurosigma Means Fourth Quarter 2012 EU Launch Of Non-invasive Epilepsy And Depression Treatment
NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that it received CE Certification for its external Trigeminal Nerve Stimulation (eTNS™) system, called the Monarch™, for the adjunctive treatment of epilepsy and major depressive disorder, for adults and children 9 years and older. NeuroSigma’s approval was supported by years of safety and compelling efficacy data generated in clinical trials conducted at the University of California, Los Angeles (UCLA) and the University of Southern California (USC).
St. Jude “Restructures” 300 Jobs Away, And Reshuffles Execs In Future-Proofing Move
St.Jude has taken the radical decision to shoe-horn its previous four divisions into two. These will be called the Implantable Electronic Systems Division (IESD), which will encompass CRM and Neuromodulation, and the Cardiovascular and Ablation Technologies Division (CATD), which will encompass Atrial Fibrillation and Cardiovascular. 300 job cuts and a host of efficiency savings are anticipated.
CE Mark And First Clinical Use For Acandis® Acclino® 1.9F Neuro Stent System
German Neurovascular device company Acandis, has announced the CE mark approval of its novel Acclino® 1.9F low profile stent system, designed for use in the interventional neurovascular field as an adjunctive product in treating intracranial aneurysms with coils.
Two CE “Thumbs Up” For Boston Scientific’s Precision™ Plus Spinal Cord Stimulator
Boston Scientific’s Precisiopn Plus Spinal Cord Stimulator is now CE marked for peripheral nerve stimulation and implantees can receive MRI head-only scans, opening up diagnostic options for clinicians in Europe.
CE Mark For Cerbomed’s Transcutaneous Vagus Nerve Stimulation Pain Relief Indication
Germans medical device company Cerbomed GmbH has received CE mark clearance for the application of transcutaneous Vagus Nerve Stimulation (t-VNS) in pain relief therapy.
Alphatec Spine’s New BridgePoint™ Spinous Process Fixation System Stabilises Spinal Segments Without Pedicle Screws
Alphatec Spine Inc. has launched its newest Minimally Invasive Surgery device, the BridgePoint Spinous Process Fixation System.
BridgePoint is designed to enable spine surgeons to immobilise and stabilise spinal segments without the need for pedicle screw and rod constructs and is intended to be an adjunct to fusion of the thoracic and lumbar spine to treat disorders resulting from degenerative disc disease, spondylolisthesis, tumor and trauma.